Skip to Main Content

After months of controversy, Pfizer (PFE) has reached a deal to sell a decades-old eye drug that it recently discontinued over long-running manufacturing concerns, a move that prompted patients to complain they were left in the lurch.

In a brief statement, the drug maker disclosed that it had transferred the rights to the eye drop — which is called phospholine iodide and is used to treat a rare form of glaucoma — to Fera Pharmaceuticals, a small privately held company run by a former executive at Sandoz, the generic unit at Novartis (NVS). Terms and a closing date for the sale were not disclosed.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment